TB-500

Also known as: Thymosin Beta-4 fragment, TB4 Ac-SDKP region

**Mechanism of Action** TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide corresponding to the actin-binding domain (Ac-SDKP region) of the endogenous protein thymosin β4. Its primary mechanism involves sequestering monomeric actin (G-actin), thereby modulating cytoskeletal dynamics and promoting cell migration. This activity enhances endothelial cell motility, angiogenesis, and extracellular matrix remodeling, while also reducing inflammation via inhibition of pro-inflammatory cytokines and oxidative stress. The peptide upregulates focal adhesion kinase (FAK) and integrin-linked kinase (ILK) signaling, facilitating tissue repair processes. **Key Research Findings** Preclinical studies demonstrate TB-500 accelerates wound healing, corneal repair, and cardiac recovery post-ischemia. In rodent models, it reduces infarct size and improves cardiac function after myocardial infarction by promoting neovascularization and reducing fibrosis. Additionally, it enhances dermal wound closure and hair growth in murine models, with evidence of reduced scar formation. Notably, TB-500 shows synergy with other growth factors (e.g., VEGF) in angiogenesis assays. However, no human clinical trials have been completed; all data derive from *in vitro* and animal studies. **Clinical Relevance** Despite widespread use in veterinary and off-label human applications, TB-500 lacks FDA approval for any indication. Its potential utility in chronic wounds, ischemic injury, and inflammatory conditions remains unvalidated in controlled human trials. Safety data are limited, with risks including theoretical tumor promotion (via angiogenesis) and unknown long-term effects. Current evidence supports only preclinical investigation. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides